BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer.


152 Background: In the BOLERO-2 study, progression-free survival (PFS) was significantly longer with the combination of everolimus and exemestane (EVE + EXE) compared with placebo and exemestane (PBO + EXE; hazard ratio = 0.45; p < .0001). Consistent efficacy results were observed in all subgroup analyses, such as in patients with visceral metastases and… (More)
DOI: 10.1200/jco.2013.31.26_suppl.152


  • Presentations referencing similar topics